TODD STRATEGY GROUP for CELGENE CORPORATION
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report (this page) | Jan 21, 2020 | $50,000 | Replaced |
| 4th Quarter - Termination | Apr 17, 2020 | $50,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
User Fee Agreement Reauthorization.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL EDATTEL | — |
| DANIEL M TODD | — |
Medicare/Medicaid MMM
General Medicare/Medicaid Issues. Medicare reimbursement for transformative therapies. CREATES Act and FDA REMS reform. President's American Patients First Blueprint.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL EDATTEL | Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg |
| DANIEL M TODD | Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.